Suchergebnisse - "Smith, Patrick F"

PubPharm (126)

31

Applications of Influenza Viral Kinetic Modeling in Drug Development

enthalten in: Current pharmacology reports | 2017

von Lovern, M. | Minton, S. | Patel, K. | +3

32

Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics

enthalten in: British journal of clinical pharmacology | 2017

von Kamal, M. | Smith, P. | Chaiyakunapruk, N. | +12

33

Erratum for Kamal et al., A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression

enthalten in: Antimicrobial agents and chemotherapy | 2016

von Kamal, M. | Gieschke, R. | Lemenuel-Diot, A. | +3

ErratumFor: Antimicrob Agents Chemother. 2015 Sep;59(9):5388-95. - PMID 26100715

34

Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks

enthalten in: EBioMedicine | 2016

von Wollacott, A. | Boni, M. | Szretter, K. | +8

CommentIn: EBioMedicine. 2016 Mar;5:16-7. - PMID 27077102

35

Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection

enthalten in: Antiviral therapy | 2016

von Canini, L. | Guedj, J. | Chatterjee, A. | +3

36

A drug-disease model describing the effect of oseltamivir neuraminidase inhibition on influenza virus progression

enthalten in: Antimicrobial agents and chemotherapy | 2015

von Kamal, M. | Gieschke, R. | Lemenuel-Diot, A. | +3

ErratumIn: Antimicrob Agents Chemother. 2016 Mar;60(3):1953. - PMID 26921415

37

Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir

enthalten in: Clinical pharmacokinetics | 2015

von Brennan, B. | Poirier, A. | Moreira, S. | +6

38

Characterization of the Transmembrane Transport and Absolute Bioavailability of the HCV Protease Inhibitor Danoprevir

enthalten in: Clinical pharmacokinetics | 2015

von Brennan, B. | Poirier, A. | Moreira, S. | +6

39

A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV

enthalten in: Antiviral therapy | 2015

von Canini, L. | Chatterjee, A. | Guedj, J. | +4

40

Characterization of the Transmembrane Transport and Absolute Bioavailability of the HCV Protease Inhibitor Danoprevir

enthalten in: Clinical pharmacokinetics | 2014

von Brennan, B. | Poirier, A. | Moreira, S. | +6